

Hugo E Vargas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6129334/publications.pdf>

Version: 2024-02-01

150
papers

8,228
citations

50170

46
h-index

49773

87
g-index

188
all docs

188
docs citations

188
times ranked

8101
citing authors

#	ARTICLE	IF	CITATIONS
1	Admission Serum Metabolites and Thyroxine Predict Advanced Hepatic Encephalopathy in a Multicenter Inpatient Cirrhosis Cohort. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 1031-1040.e3.	2.4	7
2	Solid Organ Transplantation From SARS-CoV-2â€“infected Donors to Uninfected Recipients: A Single-center Experience. <i>Transplantation Direct</i> , 2022, 8, e1286.	0.8	16
3	Prognosis of hospitalized patients with cirrhosis and acute kidney disease. <i>Liver International</i> , 2022, , .	1.9	2
4	Increased Risk of ACLF and Inpatient Mortality in Hospitalized Patients with Cirrhosis and Hepatic Hydrothorax. <i>Digestive Diseases and Sciences</i> , 2021, 66, 3612-3618.	1.1	15
5	Progression of Stage 2 and 3 Acute Kidney Injury in Patients With Decompensated Cirrhosis and Ascites. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1661-1669.e2.	2.4	14
6	Insurance Status But Not Race and Ethnicity Are Associated With Outcomes in a Large Hospitalized Cohort of Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 565-572.e5.	2.4	7
7	Reply. <i>Liver Transplantation</i> , 2021, 27, 146-146.	1.3	0
8	Increased access to liver transplantation for patients with acute on chronic liver failure after implementation of Share 35 Rule: An analysis from the UNOS database. <i>Annals of Hepatology</i> , 2021, 23, 100288.	0.6	6
9	Admission Urinary and Serum Metabolites Predict Renal Outcomes in Hospitalized Patients With Cirrhosis. <i>Hepatology</i> , 2021, 74, 2699-2713.	3.6	27
10	Clinical Outcomes of Portosystemic Shunts on the Outcome of Liver Transplantation. <i>Liver Transplantation</i> , 2020, 26, 693-701.	1.3	13
11	Serum Levels of Metabolites Produced by Intestinal Microbes and Lipid Moieties Independently Associated With Acute-on-Chronic Liver Failure and Death in Patients With Cirrhosis. <i>Gastroenterology</i> , 2020, 159, 1715-1730.e12.	0.6	65
12	GM-CSF Neutralization With Lenzilumab in Severe COVID-19 Pneumonia. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2382-2394.	1.4	77
13	Hepatic Steatosis Resulting From LMNA-Associated Familial Lipodystrophy. <i>ACG Case Reports Journal</i> , 2020, 7, e00375.	0.2	4
14	Underutilization of Hospice in Inpatients with Cirrhosis: The NACSELD Experience. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2571-2579.	1.1	17
15	Risk of Recurrence and 10-Year Outcomes in Surgically Treated Nonmelanoma Skin Cancer in Cardiac and Liver Transplant Recipients. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 366-370.	0.6	3
16	Minimal Hepatic Encephalopathy and Mild Cognitive Impairment Worsen Quality of Life in Elderly Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 3008-3016.e2.	2.4	46
17	Hepatitis C-Positive Organs for Liver and Kidney Transplantationâ€“Emerging Data and Current Management Strategies. <i>Current Hepatology Reports</i> , 2019, 18, 228-232.	0.4	0
18	Targets to improve quality of care for patients with hepatic encephalopathy: data from a multiâ€“centre cohort. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1518-1527.	1.9	40

#	ARTICLE	IF	CITATIONS
19	Impact of Chronic Kidney Disease on Outcomes in Cirrhosis. Liver Transplantation, 2019, 25, 870-880.	1.3	55
20	Outcomes After Listing for Liver Transplant in Patients With Acute-on-Chronic Liver Failure: The Multicenter North American Consortium for the Study of End-Stage Liver Disease Experience. Liver Transplantation, 2019, 25, 571-579.	1.3	53
21	Outcomes in Patients With Cirrhosis on Primary Compared to Secondary Prophylaxis for Spontaneous Bacterial Peritonitis. American Journal of Gastroenterology, 2019, 114, 599-606.	0.2	17
22	Nosocomial Infections Are Frequent and Negatively Impact Outcomes in Hospitalized Patients With Cirrhosis. American Journal of Gastroenterology, 2019, 114, 1091-1100.	0.2	41
23	Hepatitis C Virus: No Longer a Barrier to Oncology Care. American Journal of Gastroenterology, 2019, 114, 207-208.	0.2	1
24	Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2019, 17, 756-765.e3.	2.4	89
25	Acute-on-Chronic Liver Failure: Getting Ready for Prime Time?. Hepatology, 2018, 68, 1621-1632.	3.6	86
26	Glecaprevir+Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. New England Journal of Medicine, 2018, 378, 354-369.	13.9	361
27	Prediction of Fungal Infection Development and Their Impact on Survival Using the NACSELD Cohort. American Journal of Gastroenterology, 2018, 113, 556-563.	0.2	87
28	NACSELD acute-on-chronic liver failure (NACSELD-ACLF) score predicts 30-day survival in hospitalized patients with cirrhosis. Hepatology, 2018, 67, 2367-2374.	3.6	197
29	Multicenter Experience using Ledipasvir/Sofosbuvir ± RBV to Treat HCV GT 1 Relapsers after Simeprevir and Sofosbuvir Treatment. Annals of Hepatology, 2018, 17, 815-821.	0.6	4
30	Hepatitis C Guidance 2018 Update: AASLD-IDSa Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clinical Infectious Diseases, 2018, 67, 1477-1492.	2.9	509
31	Clinical outcomes of hepatitis C treatment before and after kidney transplantation and its impact on time to transplant: A multicenter study. American Journal of Transplantation, 2018, 18, 2559-2565.	2.6	16
32	The Gastroenterologist's Guide to Management of the Post-Liver Transplant Patient. American Journal of Gastroenterology, 2018, 113, 819-828.	0.2	17
33	The Impact of Albumin Use on Resolution of Hyponatremia in Hospitalized Patients With Cirrhosis. American Journal of Gastroenterology, 2018, 113, 1339.	0.2	44
34	Hydroxycut-related Vanishing Bile Duct Syndrome. Clinical Gastroenterology and Hepatology, 2017, 15, 142-144.	2.4	8
35	Child-Turcotte-Pugh Class is Best at Stratifying Risk in Variceal Hemorrhage. Journal of Clinical Gastroenterology, 2017, 51, 446-453.	1.1	72
36	Reversal of hepatorenal syndrome type 1 with terlipressin plus albumin vs. placebo plus albumin in a pooled analysis of the <scp>OT</scp>-0401 and <scp>REVERSE</scp> randomised clinical studies. Alimentary Pharmacology and Therapeutics, 2017, 45, 1390-1402.	1.9	90

#	ARTICLE	IF	CITATIONS
37	Benefits of Direct-Acting Antivirals for Hepatitis C. <i>Annals of Internal Medicine</i> , 2017, 167, 812.	2.0	13
38	IDSA/AASLD Response to Cochrane Review on Direct-Acting Antivirals for Hepatitis C. <i>Clinical Infectious Diseases</i> , 2017, 65, 1773-1775.	2.9	11
39	Comments on cochrane review on direct-acting antivirals for hepatitis C. <i>Hepatology</i> , 2017, 66, 1016-1019.	3.6	3
40	Hepatic Encephalopathy Is Associated With Mortality in Patients With Cirrhosis Independent of Other Extrahepatic Organ Failures. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 565-574.e4.	2.4	105
41	New Therapies for Hepatitis C Virus Infection. <i>Gastroenterology and Hepatology</i> , 2017, 13, 22-31.	0.2	15
42	Hepatitis C Treatment in 2016: Reasons to Be an OPTIMIST. <i>Hepatology</i> , 2016, 64, 330-332.	3.6	3
43	Prospective Analysis of Metabolic Parameters in the Detection of Diabetes and Metabolic Syndrome in Liver Transplant Recipients. <i>Metabolic Syndrome and Related Disorders</i> , 2016, 14, 305-310.	0.5	1
44	Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1. <i>Gastroenterology</i> , 2016, 150, 1579-1589.e2.	0.6	225
45	Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. <i>Gastroenterology</i> , 2016, 150, 419-429.	0.6	166
46	Hepatitis C virus infection in nonliver solid organ transplant candidates and recipients. <i>Current Opinion in Organ Transplantation</i> , 2015, 20, 259-266.	0.8	4
47	Relationship between sarcopenia, six-minute walk distance and health-related quality of life in liver transplant candidates. <i>Clinical Transplantation</i> , 2015, 29, 134-141.	0.8	107
48	Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. <i>Gastroenterology</i> , 2015, 149, 649-659.	0.6	725
49	Care of the patient with cirrhosis. <i>Clinical Liver Disease</i> , 2015, 5, 100-104.	1.0	2
50	Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 after liver transplant. <i>Hepatology</i> , 2015, 61, 1880-1886.	3.6	166
51	Magnetic resonance elastography can discriminate normal vs. abnormal liver biopsy in candidates for live liver donation. <i>Abdominal Imaging</i> , 2015, 40, 795-802.	2.0	12
52	Gastrointestinal endoscopy in the cirrhotic patient. <i>Expert Review of Gastroenterology and Hepatology</i> , 2015, 9, 1005-1013.	1.4	4
53	Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis. <i>Hepatology</i> , 2015, 62, 1004-1012.	3.6	54
54	Docetaxel Induced Sclerosing Cholangitis. <i>Digestive Diseases and Sciences</i> , 2015, 60, 3814-3816.	1.1	18

#	ARTICLE	IF	CITATIONS
55	An Interferon-free Antiviral Regimen for HCV after Liver Transplantation. <i>New England Journal of Medicine</i> , 2014, 371, 2375-2382.	13.9	377
56	Belatacept-Based Immunosuppression in De Novo Liver Transplant Recipients: 1-Year Experience From a Phase II Randomized Study. <i>American Journal of Transplantation</i> , 2014, 14, 1817-1827.	2.6	121
57	Monitoring and Care. , 2014, , 478-493.		0
58	Vitamin D deficiency, parathyroid hormone levels, and bone disease among patients with end-stage liver disease and normal serum creatinine awaiting liver transplantation. <i>Clinical Transplantation</i> , 2014, 28, 579-584.	0.8	32
59	A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. <i>Journal of Hepatology</i> , 2014, 61, 1238-1246.	1.8	126
60	Colonoscopy in liver disease. <i>Clinical Liver Disease</i> , 2014, 4, 109-112.	1.0	1
61	Portal Vein Thrombosis in Patients with End Stage Liver Disease Awaiting Liver Transplantation: Outcome of Anticoagulation. <i>Digestive Diseases and Sciences</i> , 2013, 58, 1776-1780.	1.1	115
62	Nonsteroidal Anti-Inflammatory Drug-Induced Hepatotoxicity. <i>Clinics in Liver Disease</i> , 2013, 17, 643-656.	1.0	47
63	Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. <i>Liver Transplantation</i> , 2013, 19, 690-700.	1.3	99
64	Endoscopic treatment of anastomotic biliary strictures after living donor liver transplantation: outcomes after maximal stent therapy. <i>Gastrointestinal Endoscopy</i> , 2013, 77, 47-54.	0.5	103
65	New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients: Analysis of the UNOS/OPTN Database. <i>Journal of Transplantation</i> , 2013, 2013, 1-7.	0.3	34
66	Peginterferon-2b and Ribavirin for Hepatitis C Recurrence Postorthotopic Liver Transplantation. <i>Journal of Clinical Gastroenterology</i> , 2012, 46, 700-708.	1.1	18
67	Pretransplant Fasting Glucose Predicts New-Onset Diabetes after Liver Transplantation. <i>Journal of Transplantation</i> , 2012, 2012, 1-6.	0.3	26
68	Liver Transplant Case Report: Transgenderism and Liver Transplantation. <i>International Journal of Transgenderism</i> , 2011, 13, 45-49.	3.5	4
69	Treatment of Hepatitis C in Renal Transplantation Candidates: A Single-Center Experience. <i>Transplantation</i> , 2010, 90, 407-411.	0.5	14
70	Six-minute walk distance predicts mortality in liver transplant candidates. <i>Liver Transplantation</i> , 2010, 16, 1373-1378.	1.3	238
71	Short-Term Cardiac and Noncardiac Mortality Following Liver Transplantation. <i>Journal of Transplantation</i> , 2010, 2010, 1-7.	0.3	10
72	Treatment of hepatitis C in liver transplant recipients. <i>Liver Transplantation</i> , 2009, 15, 126-135.	1.3	29

#	ARTICLE	IF	CITATIONS
73	An unusual occurrence of giant cell hepatitis. <i>Liver Transplantation</i> , 2009, 15, 1888-1890.	1.3	6
74	Natural history of post-liver transplantation hepatitis C: A review of factors that may influence its course. <i>Liver Transplantation</i> , 2009, 15, 1872-1881.	1.3	85
75	Liver Transplantation: From Child to MELD. <i>Medical Clinics of North America</i> , 2009, 93, 931-950.	1.1	26
76	Severe Hepatotoxicity Caused by a Methasteron-containing Performance-enhancing Supplement. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 287.	1.1	20
77	Inpatient Admissions for Drug-induced Liver Injury: Results from a Single Center. <i>Digestive Diseases and Sciences</i> , 2008, 53, 1977-1982.	1.1	26
78	Persistence of Hepatitis C Virus in Peripheral Blood Mononuclear Cells of Sustained Viral Responders to Pegylated Interferon and Ribavirin Therapy. <i>Digestive Diseases and Sciences</i> , 2008, 53, 2564-2568.	1.1	20
79	Preoperative dobutamine stress echocardiographic findings and subsequent short-term adverse cardiac events after orthotopic liver transplantation. <i>Liver Transplantation</i> , 2008, 14, 886-892.	1.3	98
80	The transplantation candidate with alcohol misuse: The selection minefield. <i>Liver Transplantation</i> , 2008, 14, 1559-1560.	1.3	2
81	Esophageal capsule endoscopy for screening and surveillance of esophageal varices in patients with portal hypertension. <i>Hepatology</i> , 2008, 47, 1595-1603.	3.6	147
82	Living donor liver transplantation in polycystic liver disease. <i>Liver Transplantation</i> , 2008, 14, 680-683.	1.3	17
83	Erythropoietin Does Not Increase the Frequency of Thromboembolic Events or Hepatocellular Carcinoma in Hepatitis C Patients Treated With Combination Antiviral Therapy. <i>American Journal of Gastroenterology</i> , 2008, 103, 2161-2162.	0.2	1
84	New frontiers in small-bowel imaging: the expanding technology of capsule endoscopy and its impact in clinical gastroenterology. <i>Reviews in Gastroenterological Disorders</i> , 2008, 8, 1-14.	0.6	7
85	Should Antihepatitis B Virus Core Positive or Antihepatitis C Virus Core Positive Subjects Be Accepted as Organ Donors for Liver Transplantation?. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 66-74.	1.1	5
86	Endoscopic treatment of anastomotic biliary strictures after deceased donor liver transplantation: outcomes after maximal stent therapy. <i>Gastrointestinal Endoscopy</i> , 2007, 66, 44-51.	0.5	145
87	Transient left ventricular apical ballooning syndrome (Takotsubo cardiomyopathy) following orthotopic liver transplantation. <i>Liver Transplantation</i> , 2007, 13, 1343-1345.	1.3	36
88	Pegylated Interferon and Ribavirin Failures: Is Retreatment an Option?. <i>Digestive Diseases and Sciences</i> , 2007, 52, 732-736.	1.1	23
89	Macro-Aspartate Aminotransferase and Monoclonal Gammopathy: A Review of Two Cases. <i>Digestive Diseases and Sciences</i> , 2007, 52, 1197-1198.	1.1	14
90	Portal vein thrombosis. <i>Current Treatment Options in Gastroenterology</i> , 2007, 10, 435-443.	0.3	5

#	ARTICLE	IF	CITATIONS
91	Selection of different 5' untranslated region hepatitis C virus variants during post-transfusion and post-transplantation infection. <i>Journal of Viral Hepatitis</i> , 2006, 13, 489-498.	1.0	6
92	Liver Transplantation in the MELD Era: A Single-Center Experience. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1070-1078.	1.1	15
93	Portal Hypertension Due to a Splenic Arteriovenous Fistula: A Case Report. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1113-1116.	1.1	13
94	Living donor liver transplantation for hepatitis C-related cirrhosis: No difference in histological recurrence when compared to deceased donor liver transplantation recipients. <i>Liver Transplantation</i> , 2006, 12, 560-565.	1.3	54
95	A difficult case of primary sclerosing cholangitis. <i>Liver Transplantation</i> , 2006, 12, S65-S67.	1.3	6
96	Vitamin A toxicity: When one a day doesn't keep the doctor away. <i>Liver Transplantation</i> , 2006, 12, 1888-1891.	1.3	30
97	Artificial Neural Network and Tissue Genotyping of Hepatocellular Carcinoma in Liver-Transplant Recipients: Prediction of Recurrence. <i>Transplantation</i> , 2005, 79, 1737-1740.	0.5	19
98	Regional Variations in Peer Reviewed Liver Allocation Under the MELD System. <i>American Journal of Transplantation</i> , 2005, 5, 2244-2247.	2.6	38
99	Hepatic B-cell non-Hodgkin's lymphoma of MALT type in the liver explant of a patient with chronic hepatitis C infection. <i>Liver Transplantation</i> , 2005, 11, 796-799.	1.3	20
100	Management of hepatitis C virus infection in the setting of liver transplantation. <i>Liver Transplantation</i> , 2005, 11, 479-489.	1.3	49
101	Monitoring and Care of the Patient Before Liver Transplantation. , 2005, , 473-489.		1
102	Hepatitis C Virus Quasi-Species Dynamics Predict Progression of Fibrosis after Liver Transplantation. <i>Journal of Infectious Diseases</i> , 2004, 189, 2037-2046.	1.9	42
103	Hepatic Steatosis in Hepatitis C Virus Genotype 3 Infection: Does It Correlate with Body Mass Index, Fibrosis, and HCV Risk Factors?. <i>Digestive Diseases and Sciences</i> , 2004, 49, 25-29.	1.1	58
104	Hepatitis C Virus Recurrence in Living Donor Liver Transplant Recipients. <i>Digestive Diseases and Sciences</i> , 2004, 49, 38-41.	1.1	31
105	CASE REPORT: Primary Biliary Cirrhosis and Systemic Amyloidosis, a New Association. <i>Digestive Diseases and Sciences</i> , 2004, 49, 1196-1200.	1.1	7
106	Liver transplantation for hepatocellular carcinoma: The MELD impact. <i>Liver Transplantation</i> , 2004, 10, 36-41.	1.3	231
107	Hepatopulmonary syndrome after living donor liver transplantation and deceased donor liver transplantation: A single-center experience. <i>Liver Transplantation</i> , 2004, 10, 529-533.	1.3	17
108	Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2004, 2, 183-197.	2.4	19

#	ARTICLE	IF	CITATIONS
109	Hepatitis C virus antiviral therapy in patients with cirrhosis. <i>Gastroenterology Clinics of North America</i> , 2004, 33, 549-562.	1.0	7
110	Virologically compromised donor grafts in liver transplantation. <i>Journal of Hepatology</i> , 2004, 41, 512-521.	1.8	9
111	Hepatitis C Virus Infection with Hepatocellular Carcinoma: Not A Controversial Indication for Liver Transplantation. <i>Transplantation</i> , 2004, 78, 580-583.	0.5	8
112	Recurrent hepatitis C virus after liver transplantation. <i>Current Opinion in Organ Transplantation</i> , 2004, 9, 99-103.	0.8	0
113	Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon $\alpha 2b$ and ribavirin: an open-label series ¹ . <i>Transplantation</i> , 2004, 77, 190-194.	0.5	170
114	Natural history of hepatitis C and outcomes following liver transplantation. <i>Minerva Gastroenterologica E Dietologica</i> , 2004, 50, 51-9.	2.2	9
115	The use of hepatitis C-infected grafts in liver transplantation. <i>Liver Transplantation</i> , 2003, 9, S48-S51.	1.3	35
116	Hepatitis C virus quasispecies: Misunderstood and mistreated?. <i>Liver Transplantation</i> , 2003, 9, 1048-1052.	1.3	6
117	Controversies in the management of hepatitis C virus infection after liver transplantation. <i>Liver Transplantation</i> , 2003, 9, 1129-1144.	1.3	26
118	The real danger of lamivudine-resistant hepatitis B virus infection in the immunocompromised host. <i>Liver Transplantation</i> , 2003, 7, 279-281.	1.3	1
119	The use of virologically compromised organs in liver transplantation. <i>Clinics in Liver Disease</i> , 2003, 7, 573-584.	1.0	2
120	Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation. <i>Transplantation</i> , 2003, 76, 1487-1491.	0.5	64
121	Detection and Analysis of Hepatitis C Virus Sequences in Cerebrospinal Fluid. <i>Journal of Virology</i> , 2002, 76, 10064-10068.	1.5	145
122	Search for Hepatitis C Virus Negative-Strand RNA Sequences and Analysis of Viral Sequences in the Central Nervous System: Evidence of Replication. <i>Journal of Virology</i> , 2002, 76, 600-608.	1.5	256
123	Impact of anti-hepatitis Bc-positive grafts on the outcome of liver transplantation for HBV-related cirrhosis ¹ . <i>Transplantation</i> , 2002, 73, 1598-1602.	0.5	51
124	Impact of hepatitis B and hepatitis C on solid organ transplantation. <i>Current Opinion in Organ Transplantation</i> , 2002, 7, 325-331.	0.8	0
125	A concise update on the status of liver transplantation for hepatitis B virus: The challenges in 2002. <i>Liver Transplantation</i> , 2002, 8, 2-9.	1.3	29
126	Hepatitis C: Magnitude of the problem. <i>Liver Transplantation</i> , 2002, 8, S3-S6.	1.3	36

#	ARTICLE	IF	CITATIONS
127	Detection of hepatitis C virus sequences in brain tissue obtained in recurrent hepatitis C after liver transplantation. <i>Liver Transplantation</i> , 2002, 8, 1014-1019.	1.3	59
128	Clinical significance of elevated alpha-fetoprotein in adults and children. <i>Digestive Diseases and Sciences</i> , 2001, 46, 1709-1713.	1.1	19
129	Exposure of Hepatitis C Virus (HCV) RNA-Positive Recipients to HCV RNA-Positive Blood Donors Results in Rapid Predominance of a Single Donor Strain and Exclusion and/or Suppression of the Recipient Strain. <i>Journal of Virology</i> , 2001, 75, 2059-2066.	1.5	55
130	CHANGES IN HEPATITIS C VIRUS POPULATION IN SERUM AND PERIPHERAL BLOOD MONONUCLEAR CELLS IN CHRONICALLY INFECTED PATIENTS RECEIVING LIVER GRAFT FROM INFECTED DONORS. <i>Transplantation</i> , 2001, 72, 833-838.	0.5	15
131	Clinical and virologic outcomes of hepatitis B and C viral coinfection after liver transplantation: Effect of viral hepatitis D. <i>Liver Transplantation</i> , 2000, 6, 92-96.	1.3	22
132	Clinical and Virologic Outcomes of Hepatitis B and C Viral Coinfection After Liver Transplantation: Effect of Viral Hepatitis D. <i>Liver Transplantation</i> , 2000, 6, 92-96.	1.3	13
133	Hepatitis C for half a century. <i>Gastroenterology</i> , 2000, 119, 1405-1407.	0.6	0
134	Liver Transplantation for Variceal Hemorrhage. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 1999, 9, 347-353.	0.6	4
135	Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. <i>Gastroenterology</i> , 1999, 117, 149-153.	0.6	162
136	MANAGEMENT OF PORTAL HYPERTENSION-RELATED BLEEDING. <i>Surgical Clinics of North America</i> , 1999, 79, 1-22.	0.5	24
137	HEPATITIS C VIRUS IN PERIPHERAL BLOOD MONONUCLEAR CELLS FROM A CHRONICALLY INFECTED PATIENT RECEIVING LIVER GRAFT FROM INFECTED DONOR. <i>Transplantation</i> , 1999, 67, 627-629.	0.5	5
138	Liver transplantation for variceal hemorrhage. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 1999, 9, 347-53.	0.6	1
139	Search for hepatitis C virus extrahepatic replication sites in patients with acquired immunodeficiency syndrome: Specific detection of negative-strand viral rna in various tissues. <i>Hepatology</i> , 1998, 28, 1398-1401.	3.6	155
140	The influence of hepatitis C virus genotypes on the outcome of liver transplantation. <i>Liver Transplantation</i> , 1998, 4, 22-27.	1.9	75
141	Association between Hepatitis B Virus Core Promoter Rearrangements and Hepatocellular Carcinoma. <i>Biochemical and Biophysical Research Communications</i> , 1998, 244, 812-814.	1.0	17
142	Lack of evidence for GB virus C/hepatitis G virus replication in peripheral blood mononuclear cells. <i>Journal of Hepatology</i> , 1998, 28, 179-183.	1.8	10
143	The Presence of Active Hepatitis C Virus Replication in Lymphoid Tissue in Patients Coinfected with Human Immunodeficiency Virus Type 1. <i>Journal of Infectious Diseases</i> , 1998, 178, 1189-1192.	1.9	69
144	DETECTION OF HEPATITIS C VIRUS REPLICATION IN PERIPHERAL BLOOD MONONUCLEAR CELLS AFTER ORTHOTOPIC LIVER TRANSPLANTATION. <i>Transplantation</i> , 1998, 66, 664-666.	0.5	48

#	ARTICLE	IF	CITATIONS
145	Detection of Hepatitis G Virus Replication Sites by Using Highly Strand-Specific Tth-Based Reverse Transcriptase PCR. <i>Journal of Virology</i> , 1998, 72, 3072-3075.	1.5	66
146	Distribution of Infecting Hepatitis C Virus Genotypes in End-Stage Liver Disease Patients at a Large American Transplantation Center. <i>Journal of Infectious Diseases</i> , 1997, 175, 448-450.	1.9	24
147	Hepatitis G Virus Infection in American Patients with Cryptogenic Cirrhosis: No Evidence for Liver Replication. <i>Journal of Infectious Diseases</i> , 1997, 176, 1491-1495.	1.9	27
148	Amplification and fusion of long fragments of hepatitis C virus genome. <i>Journal of Virological Methods</i> , 1997, 68, 217-223.	1.0	9
149	HEPATITIS G VIRUS COINFECTION IN HEPATITIS C VIRUS-INFECTED LIVER TRANSPLANT RECIPIENTS1. <i>Transplantation</i> , 1997, 64, 786-788.	0.5	15
150	Antitumor effects of interleukin-2 and mismatched double-stranded RNA, individually and in combination, against a human malignant melanoma xenograft. <i>Cancer Immunology, Immunotherapy</i> , 1992, 35, 151-157.	2.0	5